Why don't we have more treatments for rare diseases?
Although there are financial incentives for the research and development of rare disease treatments, their path to approval is often rocky. The patient population for any single rare disease is so small that it's time-consuming, costly, and often impossible to recruit people for the clinical trials needed to bring a drug to market. Learn more here.
Internal documents raise concerns on Bharat Biotech vaccine; Walmart to pay $3.1B to settle opioid lawsuits
Reviewed by Knowledge World
on
November 15, 2022
Rating: 5
No comments